CD33 and acute myeloid leukemia: In recent decades, antibody-drug conjugates (ADCs) have made encouraging progress since the first approval of gemtuzumab ozogamicin (Mylotarg®) for the treatment of CD33-positive acute myeloid leukaemia (AML) patients (Lambert and Morris, 2017).